Liquid Biopsy Market Growth and Future Prospects
The global liquid biopsy market is anticipated to expand from USD 4.7 billion in 2022, growing at a robust 14.5% CAGR from 2023 to 2032. By 2032, the market is projected to reach approximately USD 18.3 billion. This growth is driven by significant advancements in cancer diagnostic technologies and an increasing preference for minimally invasive methods for cancer detection.
Download statistics of this report @ https://www.towardshealthcare.com/download-statistics/5031
AI Driving Innovation in Liquid Biopsy
AI is revolutionizing liquid biopsy, offering faster, more accurate diagnostics. Platforms using AI algorithms automate the entire workflow, from sample preparation to real-time analysis, providing actionable insights. AI helps identify mutations and biomarkers specific to a patient’s cancer, enabling personalized treatments and predicting responses to therapies.
Impact of COVID-19 on Liquid Biopsy
The COVID-19 pandemic delayed cancer screenings and diagnoses, reducing demand for liquid biopsy tests. Supply chain disruptions and healthcare resource allocation further hindered cancer care, especially in low-income countries. However, the pandemic also accelerated the use of liquid biopsy in monitoring COVID-19 patients and led to the introduction of at-home testing services, such as NeoGenomics’ mobile phlebotomy service, improving access to tests during the crisis.
Key Players in the Liquid Biopsy Market
The liquid biopsy market features several leading companies that are advancing innovations in cancer diagnostics and minimally invasive testing:
- Bio-Rad Laboratories: A leader in life science research and clinical diagnostics, Bio-Rad offers liquid biopsy solutions that enhance precision in detecting and monitoring cancer.
- Biocept Inc.: Known for its expertise in molecular diagnostics, Biocept provides specialized liquid biopsy tests that target cancer markers for improved treatment decisions.
- Guardant Health: A pioneer in blood-based biopsies, Guardant Health develops innovative tests for early cancer detection, therapy selection, and treatment monitoring.
- Illumina, Inc.: This genomics company supplies sequencing technology widely used in liquid biopsy testing, helping identify genetic mutations associated with various cancers.
- F. Hoffmann-La Roche Ltd.: Roche is a global leader in pharmaceuticals and diagnostics, offering liquid biopsy solutions that support personalized cancer care.
- Johnson & Johnson: Through its subsidiary Janssen Diagnostics, Johnson & Johnson develops technologies to improve cancer detection and monitoring using liquid biopsies.
- Laboratory Corporation of America Holdings: Commonly known as LabCorp, this major diagnostics company provides liquid biopsy services as part of its extensive laboratory offerings.
- MDxHealth SA: Specializing in molecular diagnostics, MDxHealth delivers liquid biopsy tests focused on identifying cancer biomarkers to guide treatment.
- QIAGEN N.V.: This molecular diagnostics and research company provides sample-to-insight solutions for liquid biopsies, aiding in comprehensive cancer analyses.
- Thermo Fisher Scientific Inc.: Thermo Fisher offers a range of products that support liquid biopsy, from next-generation sequencing platforms to reagents, facilitating cancer diagnostics and research.
Discover our detailed Table of Contents (TOC) for the Industry, providing a thorough examination of market segments, material, emerging technologies and key trends. Our TOC offers a structured analysis of market dynamics, emerging innovations, and regional dynamics to guide your strategic decisions in this rapidly evolving healthcare field – https://www.towardshealthcare.com/table-of-content/liquid-biopsy-an-emerging-cancer-diagnostic
To own our research study instantly, Click here @ https://www.towardshealthcare.com/price/5031
You can place an order or ask any questions, please feel free to contact us at sales@towardshealthcare.com
About Us
Towards Healthcare is a leading global provider of technological solutions, clinical research services, and advanced analytics to the healthcare sector, committed to forming creative connections that result in actionable insights and creative innovations. We are a global strategy consulting firm that assists business leaders in gaining a competitive edge and accelerating growth. We are a provider of technological solutions, clinical research services, and advanced analytics to the healthcare sector, committed to forming creative connections that result in actionable insights and creative innovations.
Visit Dental Specifics: https://www.towardsdental.com
Explore the comprehensive statistics and insights on healthcare industry data and its associated segmentation: Get a Subscription
For Latest Update Follow Us: https://www.linkedin.com/company/towards-healthcare
